257 related articles for article (PubMed ID: 25891704)
1. Clinical implications of angiotensin II type 1 receptor antibodies in antibody-mediated rejection without detectable donor-specific HLA antibodies after renal transplantation.
Lee J; Park Y; Kim BS; Lee JG; Kim HJ; Kim YS; Huh KH
Transplant Proc; 2015 Apr; 47(3):649-52. PubMed ID: 25891704
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
3. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes.
Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Bartoszek D; Zabińska M; Myszka M; Zmonarski S; Protasiewicz M; Nowakowska B; Hałoń A; Chudoba P; Klinger M
Transpl Int; 2014 Oct; 27(10):1029-38. PubMed ID: 24909812
[TBL] [Abstract][Full Text] [Related]
4. Investigation of Serum Angiotensin II Type 1 Receptor Antibodies at the Time of Renal Allograft Rejection.
Lee H; Kim JI; Moon IS; Chung BH; Yang CW; Kim Y; Han K; Oh EJ
Ann Lab Med; 2015 May; 35(3):314-20. PubMed ID: 25932439
[TBL] [Abstract][Full Text] [Related]
5. A 3-Center Study Reveals New Insights Into the Impact of Non-HLA Antibodies on Lung Transplantation Outcome.
Reinsmoen NL; Mirocha J; Ensor CR; Marrari M; Chaux G; Levine DJ; Zhang X; Zeevi A
Transplantation; 2017 Jun; 101(6):1215-1221. PubMed ID: 27973391
[TBL] [Abstract][Full Text] [Related]
6. Antibody-Mediated Rejection in Kidney Transplantation Without Evidence of Anti-HLA Antibodies?
Irure J; López-Hoyos M; Rodrigo E; Gómez-Román J; Ruiz JC; Arias M; San Segundo D
Transplant Proc; 2016 Nov; 48(9):2888-2890. PubMed ID: 27932099
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiotensin type 1 receptor antibodies associated with antibody-mediated rejection in patients without preformed HLA-donor-specific antibody.
In JW; Park H; Rho EY; Shin S; Park KU; Park MH; Song EY
Transplant Proc; 2014 Dec; 46(10):3371-4. PubMed ID: 25498054
[TBL] [Abstract][Full Text] [Related]
8. Non-HLA antibodies: angiotensin II type 1 receptor (anti-AT1R) and endothelin-1 type A receptor (anti-ETAR) are associated with renal allograft injury and graft loss.
Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Zmonarski S; Mazanowska O; Krajewska M; Bartoszek D; Zabińska M; Myszka M; Kamińska M; Hałoń A; Dawiskiba T; Szyber P; Sas A; Klinger M
Transplant Proc; 2014 Oct; 46(8):2618-21. PubMed ID: 25380879
[TBL] [Abstract][Full Text] [Related]
9. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients.
Lefaucheur C; Viglietti D; Bouatou Y; Philippe A; Pievani D; Aubert O; Duong Van Huyen JP; Taupin JL; Glotz D; Legendre C; Loupy A; Halloran PF; Dragun D
Kidney Int; 2019 Jul; 96(1):189-201. PubMed ID: 31005275
[TBL] [Abstract][Full Text] [Related]
10. Histopathologic changes in anti-angiotensin II type 1 receptor antibody-positive kidney transplant recipients with acute rejection and no donor specific HLA antibodies.
Lim MA; Palmer M; Trofe-Clark J; Bloom RD; Jackson A; Philogene MC; Kamoun M
Hum Immunol; 2017 Apr; 78(4):350-356. PubMed ID: 28284829
[TBL] [Abstract][Full Text] [Related]
11. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Antibodies Directed Against Two GPCRs, Anti-AT1R and Anti-ETAR, on Kidney Transplant Outcome.
El Band JEK; Llorente S; Martinez-Garcia P; Alfaro R; Jimenez-Coll V; Boix F; Galián JA; Martinez-Banaclocha H; Botella C; Moya-Quiles MR; Minguela A; Legaz I; Muro M
Curr Protein Pept Sci; 2021; 22(10):745-757. PubMed ID: 34967284
[TBL] [Abstract][Full Text] [Related]
13. Deleterious effect of anti-angiotensin II type 1 receptor antibodies detected pretransplant on kidney graft outcomes is both proper and synergistic with donor-specific anti-HLA antibodies.
Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
Nephrology (Carlton); 2019 Mar; 24(3):347-356. PubMed ID: 29451342
[TBL] [Abstract][Full Text] [Related]
14. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
[TBL] [Abstract][Full Text] [Related]
15. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
[TBL] [Abstract][Full Text] [Related]
16. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss.
Giral M; Foucher Y; Dufay A; Duong Van Huyen JP; Renaudin K; Moreau A; Philippe A; Hegner B; Dechend R; Heidecke H; Brouard S; Cesbron A; Castagnet S; Devys A; Soulillou JP; Dragun D
Am J Transplant; 2013 Oct; 13(10):2567-76. PubMed ID: 23919486
[TBL] [Abstract][Full Text] [Related]
17. Association of angiotensin II type 1 receptor antibodies with graft histology, function and survival in paediatric renal transplant recipients.
Fichtner A; Süsal C; Schröder C; Höcker B; Rieger S; Waldherr R; Westhoff JH; Sander A; Dragun D; Tönshoff B
Nephrol Dial Transplant; 2018 Jun; 33(6):1065-1072. PubMed ID: 29444269
[TBL] [Abstract][Full Text] [Related]
18. Anti-Angiotensin II Type 1 Receptor and Anti-Endothelial Cell Antibodies: A Cross-Sectional Analysis of Pathological Findings in Allograft Biopsies.
Philogene MC; Bagnasco S; Kraus ES; Montgomery RA; Dragun D; Leffell MS; Zachary AA; Jackson AM
Transplantation; 2017 Mar; 101(3):608-615. PubMed ID: 27222934
[TBL] [Abstract][Full Text] [Related]
19. Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome.
Reinsmoen NL; Lai CH; Mirocha J; Cao K; Ong G; Naim M; Wang Q; Haas M; Rafiei M; Czer L; Patel J; Kobashigawa J
Transplantation; 2014 Mar; 97(5):595-601. PubMed ID: 24162250
[TBL] [Abstract][Full Text] [Related]
20. The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation.
Lee J; Huh KH; Park Y; Park BG; Yang J; Jeong JC; Lee J; Park JB; Cho JH; Lee S; Ro H; Han SY; Kim MS; Kim YS; Kim SJ; Kim CD; Chung W; Park SB; Ahn C;
Nephrol Dial Transplant; 2017 Jul; 32(7):1244-1250. PubMed ID: 26546592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
